Results demonstrate the importance of ultra-sensitive ctDNA detection in lung cancer Personalis, Inc. (NASDAQ:PSNL), in collaboration with Professor Charles Swanton and his colleagues at London's Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine. In this groundbreaking study funded by Cancer Research UK, co-authors Black and Bartha et al. highlight advancements in lung cancer detection using NeXT Personal®, an ultra-sensitive personalized test designed to detect small traces of circulating tumor DNA (ctDNA) in the blood of cancer patients and survivors. In this study, NeXT Personal was used to analyze pre

Full year revenue of ~$84.6 million represents a 15% year-over-year increase Cash balance of ~$185.0 million expected to provide runway to cash flow break-even Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2024 and preliminary cash balance. Preliminary Full Year 2024 Revenue Revenue of approximately $84.6 million for the full year of 2024 compared with $73.5 million for the full year of 2023, an increase of 15%, and above the company's previous full year guidance range of $83.0 to $84.0 million Revenue from pharma tests and services, enterp

USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases. This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care—particularly delays in screenings, diagnoses, and treatments—have likely exacerbated

Personalis, Inc. (NASDAQ:PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company's business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis' ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT), being jointly developed by Merck and Moderna. Merck has agreed to purchase $50 million of Personalis common stock in a private placement at a price of $3.56 per share, which was the last reported closing price of Perso

Expanded collaboration to yield greater biopharma access to Personalis' MRD solution Personalis, Inc. (NASDAQ:PSNL) and Tempus AI, Inc. (NASDAQ:TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. Followin

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Fireside Chat Time: 12:30 pm Eastern Time Location: The Lotte New York Palace in New York, NY TD Cowen Diagnosing Tomorrow: Tools & Technologies for the Next Decade Date: Thursday, December 12, 2024 Panel Topic: MRD - The Future Tech Stack Panel Time: 1:30 pm Eastern Time Location: One Vanderbilt in New York, NY About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthro

41% Year-over-Year Increase in Revenue Driven by Strong Biopharma Growth of 96% Raising 2024 Revenue Guidance Due to Accelerating Growth Cash Balance of $143.7 Million Extends Expected Runway Into First-Half of 2027 Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2024, and provided recent business accomplishments. Recent Business Accomplishments Raised approximately $35.0 million in net financing proceeds from Tempus AI, Inc. (Tempus), consisting of $18.4 million from Tempus' exercise of all its common stock warrants, at an average price of $2.00 per share, and $16.6 millio

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the Stifel 2024 Healthcare Conference on Tuesday, November 19, at 10:55 a.m. Eastern Time in New York, NY at the Lotte New York Palace Hotel. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the co

Results continue to demonstrate the importance of ultra-sensitive ctDNA detection in lung cancer and immunotherapy Personalis, Inc. (NASDAQ:PSNL), a leader in MRD testing, announced findings presented this week at the European Society of Medical Oncology Congress (ESMO) Congress 2024 in Barcelona, Spain. Personalis' NeXT Personal assay was designed to detect and monitor residual and recurrent disease (MRD) in cancer patients by detecting very small traces of circulating tumor DNA (ctDNA) in the blood. It was launched to the clinic in late 2023 and is being co-commercialized in partnership with Tempus AI, Inc. Two studies were presented at ESMO further demonstrating the importance of using

4 - Personalis, Inc. (0001527753) (Issuer)

SC 13G/A - Personalis, Inc. (0001527753) (Subject)

SC 13G - Personalis, Inc. (0001527753) (Subject)

SC 13D/A - Personalis, Inc. (0001527753) (Subject)

SC 13G/A - Personalis, Inc. (0001527753) (Subject)

SC 13G/A - Personalis, Inc. (0001527753) (Subject)

SC 13G/A - Personalis, Inc. (0001527753) (Subject)

SC 13G - Personalis, Inc. (0001527753) (Subject)

SC 13G/A - Personalis, Inc. (0001527753) (Subject)

SC 13G/A - Personalis, Inc. (0001527753) (Subject)

SC 13G/A - Personalis, Inc. (0001527753) (Subject)

Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se

Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced the appointment of Christopher Hall as SVP and Head, Diagnostics Business. As part of the executive leadership team, Hall will drive the vision and strategy for commercializing Personalis' diagnostic product offerings. "We are excited to welcome Chris given his immense experience in successfully scaling diagnostics businesses," said John West, CEO of Personalis. "He is a great fit for Personalis as we expand into the clinical market. His track record is impressive – from CEO of a health technology start-up focused on multi-omics, to prior roles including leading Veracyte's commercial organization, lau

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position of Vice President of Diagnostic Sales. This appointment supports the company's objective to accelerate expansion into the clinical market. "We are excited to welcome James to the team as he brings more than 20 years of successful commercial experience in oncology molecular diagnostics," said John West, CEO and co-founder of Personalis. "James will lead our clinical commercial efforts to pursue business with health care systems and oncologists in the United States. His focus will include growing our clinical test volume as we als

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced the appointment of Robert Bruce to the newly created position of Vice President of Reimbursement. "We are very pleased to welcome Bob and his impressive public and private payer reimbursement strategy skill set to the Personalis team," said John West, Chief Executive Officer. "He brings over 25 years of experience in all aspects of reimbursement execution within clinical molecular diagnostic testing, including offerings for Molecular Residual Disease assessment and monitoring." Mr. Bruce joins Personalis from Clinical Genomics, where he served as VP Reimbursement and Interim Chief Financial Officer.

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 100,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Although Personalis has been contracted by the VA MVP since 2012, the program has accelerated and over 50,000 of these genomes have been delivered in 2020. “The VA MVP is the largest whole genome sequencing project in the United States and this is a significant milestone for both the program and for Personalis,” said John West, Chief Executive Officer. “Population-scale sequencing p

Needham upgraded Personalis from Hold to Buy and set a new price target of $8.00

Needham upgraded Personalis from Hold to Buy

Oppenheimer reiterated coverage of Personalis with a rating of Outperform and set a new price target of $24.00 from $30.00 previously

Citigroup reiterated coverage of Personalis with a rating of Buy and set a new price target of $18.00 from $30.00 previously

HC Wainwright & Co. reiterated coverage of Personalis with a rating of Buy and set a new price target of $38.00 from $50.00 previously

BofA Securities upgraded Personalis from Neutral to Buy and set a new price target of $23.00 from $27.00 previously

Morgan Stanley downgraded Personalis from Overweight to Equal-Weight and set a new price target of $25.00 from $32.00 previously

Morgan Stanley downgraded Personalis from Overweight to Equal-Weight

Needham downgraded Personalis from Buy to Hold

Cowen resumed coverage of Personalis with a rating of Outperform